Search research articles
Contact Us
Filters
Showing results (71-80 of 82) with videos related to
Page
of 9
Sort By:
Pharmacology Research & Perspectives
|
June 3, 2023
Management of pharmacovigilance during the COVID-19 pandemic crisis by the safety department of an academic sponsor: Lessons learnt and challenges from the EU DisCoVeRy clinical trial
Noémie Mercier, Drifa Belhadi, Aline DeChanet, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
March 29, 2024
Cardiac Adverse Events and Remdesivir in Hospitalized Patients With COVID-19: A Post Hoc Safety Analysis of the Randomized DisCoVeRy Trial
Vida Terzić, Joe Miantezila Basilua, Nicolas Billard, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
January 3, 2025
Clinical Characterization and Outcomes of Human Clade IIb Mpox Virus Disease: A European Multicenter Mpox Observational Cohort Study (MOSAIC)
Elise Pesonel, Cédric Laouénan, Laetitia Guiraud, et al.
British Journal of Clinical Pharmacology
|
January 21, 2023
Implementation of a centralized pharmacovigilance system in academic pan-European clinical trials: Experience from EU-Response and conect4children consortia
Vida Terzić, Léa Levoyer, Mélanie Figarella, et al.
The Lancet. Respiratory Medicine
|
February 24, 2023
Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials
Alain Amstutz, Benjamin Speich, France Mentré, et al.
The Lancet. Respiratory Medicine
|
May 16, 2025
Effects of Janus kinase inhibitors in adults admitted to hospital due to COVID-19: a systematic review and individual participant data meta-analysis of randomised clinical trials
Alain Amstutz, Stefan Schandelmaier, Hannah Ewald, et al.
The Lancet. Respiratory Medicine
|
November 10, 2021
Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial
Jozefien Declercq, Karel F A Van Damme, Elisabeth De Leeuw, et al.
Scientific Reports
|
April 24, 2025
sST2 is a key outcome biomarker in COVID-19: insights from discovery randomized trial
David M Smadja, Clément R Massonnaud, Aurélien Philippe, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
|
May 28, 2021
An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19
Florence Ader, Nathan Peiffer-Smadja, Julien Poissy, et al.
Lancet (London, England)
|
January 23, 2022
Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial
Lulu Bravo, Igor Smolenov, Htay Htay Han, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 82) with videos related to
Sort By:
Page
of 9
Pharmacology Research & Perspectives
|
June 3, 2023
Management of pharmacovigilance during the COVID-19 pandemic crisis by the safety department of an academic sponsor: Lessons learnt and challenges from the EU DisCoVeRy clinical trial
Noémie Mercier, Drifa Belhadi, Aline DeChanet, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
March 29, 2024
Cardiac Adverse Events and Remdesivir in Hospitalized Patients With COVID-19: A Post Hoc Safety Analysis of the Randomized DisCoVeRy Trial
Vida Terzić, Joe Miantezila Basilua, Nicolas Billard, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
January 3, 2025
Clinical Characterization and Outcomes of Human Clade IIb Mpox Virus Disease: A European Multicenter Mpox Observational Cohort Study (MOSAIC)
Elise Pesonel, Cédric Laouénan, Laetitia Guiraud, et al.
British Journal of Clinical Pharmacology
|
January 21, 2023
Implementation of a centralized pharmacovigilance system in academic pan-European clinical trials: Experience from EU-Response and conect4children consortia
Vida Terzić, Léa Levoyer, Mélanie Figarella, et al.
The Lancet. Respiratory Medicine
|
February 24, 2023
Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials
Alain Amstutz, Benjamin Speich, France Mentré, et al.
The Lancet. Respiratory Medicine
|
May 16, 2025
Effects of Janus kinase inhibitors in adults admitted to hospital due to COVID-19: a systematic review and individual participant data meta-analysis of randomised clinical trials
Alain Amstutz, Stefan Schandelmaier, Hannah Ewald, et al.
The Lancet. Respiratory Medicine
|
November 10, 2021
Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial
Jozefien Declercq, Karel F A Van Damme, Elisabeth De Leeuw, et al.
Scientific Reports
|
April 24, 2025
sST2 is a key outcome biomarker in COVID-19: insights from discovery randomized trial
David M Smadja, Clément R Massonnaud, Aurélien Philippe, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
|
May 28, 2021
An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19
Florence Ader, Nathan Peiffer-Smadja, Julien Poissy, et al.
Lancet (London, England)
|
January 23, 2022
Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial
Lulu Bravo, Igor Smolenov, Htay Htay Han, et al.
Page
of 9